drugset / Trial / NCT03524937

Prevention of Delirium in Intensive Care by Melatonin

NCT03524937

Phase 2/3 Completed 355 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, Phase 2b/3 two-part adaptive clinical trial. The trial is designed to investigate the pharmacokinetics and the efficacy of multiple dosing regimens of melatonin and to confirm the efficacy and safety of one dosing regimen in prevention for delirium.

Timeline

Start
2019-02-01
Primary completion
2021-05-01
Completion
2021-05-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 0.3 mg Oral
Subject Melatonin Small molecule 3 mg Oral

Indications

No indication recorded.